Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Alprazolam,Inapplicable
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
November 23, 2022
Lead Product(s) : Alprazolam,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Alprazolam,Inapplicable
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
October 14, 2021
Lead Product(s) : Alprazolam,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Alprazolam,Inapplicable
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
October 13, 2021
Lead Product(s) : Alprazolam,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cannabidiol,Tetrahydrocannabinol,Alprazolam
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : National Highway Traffic Safety Administration | Acclaro Research Solutions | Cognitive Research Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Validation of the Drug Impaired Driving Scenario (DIDS) on the CRCDS-miniSim
Details : Undisclosed
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
July 21, 2021
Lead Product(s) : Cannabidiol,Tetrahydrocannabinol,Alprazolam
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : National Highway Traffic Safety Administration | Acclaro Research Solutions | Cognitive Research Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Alprazolam,Inapplicable
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
April 23, 2021
Lead Product(s) : Alprazolam,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Alprazolam,Inapplicable
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
March 17, 2021
Lead Product(s) : Alprazolam,Inapplicable
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Alprazolam,Inapplicable
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
March 04, 2021
Lead Product(s) : Alprazolam,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Alprazolam,Inapplicable
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Staccato alprazolam has demonstrated the ability to rapidly terminate seizures in patients with epilepsy in two minutes or less and prevent recurrence of seizure within two hours.
Product Name : Staccato
Product Type : Controlled Substance
Upfront Cash : Inapplicable
December 03, 2020
Lead Product(s) : Alprazolam,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Gamma-Aminobutyric Acid,Alprazolam
Therapeutic Area : Endocrinology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The Swedish Medical Products Agency has approved an amendment to ReGenerate-1 to investigate Remygen®'s preventive effects on hypoglycaemia (severely reduced blood sugar level) in individuals with long-term type 1 diabetes.
Product Name : Remygen
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 24, 2020
Lead Product(s) : Gamma-Aminobutyric Acid,Alprazolam
Therapeutic Area : Endocrinology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Alprazolam,Inapplicable
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : UCB Pharma S.A
Deal Size : $270.0 million
Deal Type : Acquisition
UCB Acquires Engage Therapeutics for Staccato® Alprazolam
Details : With is acquisition, UCB will have world-wide rights to Staccato[®] Alprazolam and would perform further clinical development, submission, launch and commercialization of Staccato[®] Alprazolam.
Product Name : Staccato
Product Type : Controlled Substance
Upfront Cash : $125.0 million
May 06, 2020
Lead Product(s) : Alprazolam,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : UCB Pharma S.A
Deal Size : $270.0 million
Deal Type : Acquisition